ARBOLT-A 40/5 mg price in UAE

Overview

Welcome to Dwaey, specifically on ARBOLT-A 40/5 mg Tablet/Film-coated page.
This medicine contains an important and useful components, as it consists of Olmesartan Medoxomil , Amlodipine Besylate.
ARBOLT-A 40/5 mg is available in the market in concentration 40 mg/tablet, 5 mg/tablet and in the form of Tablet/Film-coated.

ANNORA PHARMA FZ-LLC is the producer of ARBOLT-A 40/5 mg and it is imported from UAE, The most popular alternatives of ARBOLT-A 40/5 mg are listed downward .

Mode Of Action

Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart.

Indication

Hypertension
Diabetic nephropathy

Precaution

Drugs that act on renin-angiotensin system can cause fetal injury and death when used in 2nd and 3rd trimesters of pregnancy. Olmesartan medoxomil should be discontinued as soon as possible once pregnancy is detected. Symptomatic hypotension may occur in patients who are volume- and/or salt-depleted. May be associated with oliguria, progressive azotaemia, and acute renal failure (rare). Patients with bilateral or unilateral renal artery stenosis may have increased risk of severe hypotension and renal insufficiency. Caution in renal impairment; monitor serum creatinine and potassium levels periodically. Avoid use in severe renal impairment (CrCl< 20 mL/min) and severe hepatic impairment. Caution in patients with aortic or mitral valve stenosis, obstructive hypertrophic cardiomyopathy. Patients with primary aldosteronism may not respond to angiotensin receptor antagonist. Not recommended in lactation. Lactation: No human data; use with caution

Side Effects

1-10% Dizziness
Headache
Fatigue
Diarrhea
Hyperglycemia
Hypertriglyceridemia
Back pain
Bronchitis
Inflicted injury
Flulike symptoms
Pharyngitis
Rhinitis
Sinusitis
Upper respiratory tract infection (URTI) Frequency Not Defined (selected) Anaphylactic reaction
Angioedema
Facial edema
Rhabdomyolysis
Hyperkalemia
Tachycardia
Hypercholesterolemia
Gastroenteritis
Hyperlipidemia Potentially Fatal: Acute renal failure.

Contra indication

Pregnancy (2nd and 3rd trimesters); biliary obstruction.

Pregnancy and lactation

Pregnancy category: C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks

Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D

Interaction

Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.